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Abstract
Background:  Randomised controlled clinical trials are performed to resolve uncertainty
concerning comparator interventions. Appropriate acknowledgment of uncertainty enables the
concurrent achievement of two goals : the acquisition of valuable scientific knowledge and an
optimum treatment choice for the patient-participant. The ethical recruitment of patients requires
the presence of clinical equipoise. This involves the appropriate choice of a control intervention,
particularly when unapproved drugs or innovative interventions are being evaluated.
Discussion:  We argue that the choice of a control intervention should be supported by a
systematic review of the relevant literature and, where necessary, solicitation of the informed
beliefs of clinical experts through formal surveys and publication of the proposed trial's protocol.
Summary: When clinical equipoise is present, physicians may confidently propose trial enrollment
to their eligible patients as an act of therapeutic beneficence.
Background
Randomised clinical trials (RCTs) are performed to
resolve uncertainty concerning the relative efficacy of
comparator interventions. They are conducted as "piv-
otal" trials in support of an application for marketing of
an investigational agent, to evaluate the relative effective-
ness of a novel treatment strategy, or the relative merits of
commonly used interventions. Each year, thousands of
human participants are recruited for RCTs in the context
of established patient-physician relationships, in which
patients seek medical care and physicians are bound by a
duty of therapeutic beneficence. How is the latter to be
reconciled with the need to recruit patients for trials?
Uncertainty in RCTs may be considered at three levels : the
community of "expert" practitioners and trialists, who
propose a trial for its resolution; the individual practi-
tioner, who has to decide whether to participate in a trial,
and whether to offer enrolment to particular patients; and
the patient, who has to decide whether to accept an offer
of enrolment [1] The concept of clinical equipoise [2]
denotes the level of community uncertainty, and has been
proposed as a moral requirement for the recruitment of
patients.[3] The presence or absence of community uncer-
tainty is thus of particular interest to research ethics com-
mittees which must approve the conduct of clinical trials.
If one of the interventions in a proposed trial is known to
be superior, considering both effectiveness and adverse
effects, a proposed RCT cannot be justified. The appropri-
ate acknowledgment of uncertainty enables the concur-
rent achievement of two objectives : the acquisition of
valuable scientific knowledge (the trialist's primary goal),
and the best treatment choice (the patient's primary goal)
under conditions of uncertainty.[4]
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If a trial is to evaluate an unapproved drug or biological
agent (available only in the context of a trial), or novel
intervention, positive evidence of efficacy and safety from
preliminary non-clinical and clinical testing must be suf-
ficient to support the conduct of a RCT. If so, then from
the point of view of trial design the ethical requirement of
clinical equipoise is expressed as an appropriate choice of
a control intervention. Appraisal of this choice should
explicitly be made by research ethics committees.
In proposing the imperative of clinical equipoise for the
conduct of a RCT, Freedman [2] also emphasized the need
for designing and conducting the trial in a manner that
ensures that equipoise will be disturbed if one of the com-
parator interventions is indeed superior. Thus, the trial
must meet the requirement of scientific (internal and
external) validity.[5] With respect to scientific validity,
there is substantial guidance for the trialist, including the
CONSORT statement [6] applicable to the reporting of
RCTs. The CONSORT statement's checklist of items com-
prehensively addresses the notion of internal validity
(avoidance of bias in the form of systematic error). How-
ever, a trial may be judged methodologically valid, but
may not address uncertainty of clinical relevance to the
patients being recruited, or, by extension, the health of
future patients, similarly situated [7] The choice of a con-
trol intervention is a critical design feature in a RCT – fac-
tors that should inform the appropriate choice of a
control intervention are summarized in panel 1. The first
factor – existent knowledge concerning the relative effi-
cacy of the proposed experimental and control interven-
tions – is a principal focus of the ensuing discussion.
Discussion
In a scheme for the ethical analysis of risk of harm in a
proposed randomized controlled trial by research ethics
committees, Weijer [8] describes three determinations
necessary to consider a trial approvable: therapeutic
research components must be justified by the direct pros-
pect of health-related benefits (a harm-benefit calculus);
non-therapeutic research components must be justified
by the prospect of acquiring valuable knowledge (a harm-
knowledge calculus); and clinical equipoise must be
present. With respect to the latter, Weijer describes how a
research ethics committee may, in selected cases, "require
a search of the medical literature or consultation with rel-
evant experts who have no connection with the study or
its sponsor."
Clinical equipoise may be considered a state of reasoned
epistemic uncertainty in the clinical community concern-
ing a body of factual evidence about treatment effects – a
claim susceptible to critical appraisal. Our core argument
is that the choice of a control intervention should be sup-
ported by the application of one or more of the activities
in panel 2. The methods used to choose a control inter-
vention should be included in the published report of a
trial's results.
Systematic review of the literature
The conduct of clinical research should be informed by
existent knowledge. This will ensure that certain require-
ments for the ethical conduct of clinical research are met :
social and scientific value, a favorable harm-benefit ratio,
and respect for potential or enrolled participants [5]. With
respect to clinical trials, Herxheimer [9] cogently
expressed this need as follows: "...a proposal for a trial
should be accompanied by a thorough review of all previ-
ous trials that have examined the same and closely related
questions. Only in the light of such a review can a sound
opinion be given on whether the proposal is ethical." Reli-
ance on the opinions of one or two "experts" only – a
common strategy in research ethics committee delibera-
tions – to assess whether clinical equipoise is present is
unsatisfactory. Previous work has shown dissonance
between the opinions of experts and the state of existent
knowledge as revealed by a systematic review or meta-
analysis of the relevant literature.[10] The factors in Panel
1 applicable to the proposed trial should be addressed in
relation to a systematic review.
The systematic review should be conducted, reported and
submitted to research ethics committees by a principal tri-
alist(s) in accordance with well established procedures
[11], or a claim of clinical equipoise may be supported by
reference to an up-to-date systematic review(s) published
in the peer-reviewed literature, or produced under the
aegis of organizations like the Cochrane Collaboration.
Panel 1: Factors that determine the proper choice of a control 
intervention for a trial
• Existent knowledge concerning the relative efficacy of the proposed 
experimental and control interventions
• The dose (for drugs) and mechanism of control intervention applica-
tion
• Appreciation of the range of interventions available for the condition 
being evaluated (drug versus non-drug therapies)
• Current medical practice in the setting in which the trial is con-
ducted
Panel 2: Justifying the choice of a control intervention for a trial
• Systematic review of the relevant literature
• Cumulative meta-analysis of completed trials
• Formal survey of expert clinical practitioners
• Publication of the trial's protocol to solicit critical appraisalBMC Medical Research Methodology 2003, 3 http://www.biomedcentral.com/1471-2288/3/7
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Members of research ethics committees need to under-
stand the essential components of a systematic review (an
appropriate literature search strategy in particular), and be
able to assess the general quality of a review submitted in
support of a trial. Committee members with special exper-
tise in the medical area under investigation should con-
firm the adequacy of the systematic review in light of their
personal knowledge.
We anticipate an argument that the requirement for an
up-to-date systematic review is unjustifiably stringent –
too demanding of investigators' time, may necessitate
additional financial resources, and will delay the comple-
tion of important trials. These are relevant concerns, but
we do not find them persuasive. Any delay in initiating a
clinical trial will be offset by greater confidence in the
value and relevance of the research. More investigators
and ethics committee members will acquire valuable
skills relative to the conduct and appraisal of research syn-
thesis. The consequences of a limited or selective review of
the published literature may be severe as indicated by the
tragic death of a research volunteer in research involving
hexamethonium. A systematic literature search using
explicit methods would have uncovered 16 relevant
papers concerning pulmonary complications associated
with its use.[12] Evidence from recently completed trials
(controlled and uncontrolled) may either disturb existent
community equipoise, or may further support a state of
community equipoise, justifying the conduct of a RCT.
Finally, as Chalmers has described, an up-to-date system-
atic review will also be of substantial value in two other
important ways: to enhance interim results monitoring of
an ongoing trial, and to facilitate the informative report-
ing of a trial's results in relation to existent
knowledge.[13]
Cumulative meta-analysis of completed trials
The state of knowledge concerning treatment effects
changes as evidence is cumulated and synthesized. Uncer-
tainty exits in degrees along a continuum – evidence sup-
portive of a treatment option may vary between "tentative
or preliminary" and "robust or convincing." This notion is
particularly relevant when the place of new interventions
is being considered.
The statistical technique of cumulative meta-analysis is
applicable to the assessment of treatment effects as they
are revealed by the outcomes of successively completed
clinical trials. It may be considered the product of per-
forming a new meta-analysis every time a new trial is
added to a series of trials.[14] The use of this technique is
illustrated in an analysis of trials evaluating streptokinase
in myocardial infarction.[15] Lau and colleagues found
33 relevant trials, and concluded that uncertainty about
its efficacy had been resolved after the completion of 15
trials, and long before its ultimate approval by the U.S.
Food and Drug Administration. Half of the 32,660 partic-
ipants in the 18 succeeding trials were randomized to a
no-treatment or placebo arm, and the authors made the
salient observation that "Against the need for replication
to learn more about subgroups [from large trials] must be
weighed the propriety of assigning patients to a control
group instead of giving them a treatment shown to be
effective by the meta-analysis of a number of small trials."
More recently, Clark and colleagues performed a cumula-
tive meta-analysis of placebo-controlled trials evaluating
the efficacy of erythropoietin in cancer-related ane-
mia.[16] They concluded that uncertainty about its effi-
cacy could conservatively have been considered resolved
after the results of 6 of the19 trials found had been
reported.
Investigators and research ethics committees need to be
aware of situations when a cumulative meta-analysis
should be done in support of a proposal to conduct a RCT.
This necessitates a preliminary systematic search for pub-
lished and unpublished results of completed trials, the
methods and results of which should be submitted for
committee review.
Formal survey of clinical practitioners
Trialists may need to evaluate novel interventions in areas
of clinical care in which there are no or only a few com-
pleted trials to guide the design and conduct of a pro-
posed RCT. Because a RCT is performed to address
uncertainty about comparator interventions, the choice of
control intervention should adequately reflect, to the
extent possible, "current standard medical practice." We
show the difficulty of defining the latter in certain circum-
stances with an example.
The ARDS Clinical Network performed a multi-centre
clinical trial between 1996 and 1999 evaluating two tidal-
volume strategies (6 ml/kg versus 12 ml/kg) in patients
with ARDS. [17]The trial result published in 2000 pro-
vided evidence in support of the relative superiority of the
lower tidal-volume strategy. This trial has informed subse-
quent clinical practice. Concerns about the choice of the
control intervention have been raised, most recently by
Eichacker and colleagues [18], who argue that the 12 ml/
kg tidal volume strategy was inappropriately high, and did
not reflect "current clinical practice" at the time the trial
was conducted. It is not our purpose here to evaluate the
relative merits of the opposing arguments.()[18,19], but
note that both parties refer, in part, to a practice survey
conducted in 1992, and published in 1996 [20], in sup-
port of their respective positions. The survey solicited
opinions regarding several factors important in the diag-
nosis and treatment of ARDS, including the application ofBMC Medical Research Methodology 2003, 3 http://www.biomedcentral.com/1471-2288/3/7
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ventilator therapy. Although the survey was not con-
ducted in support of the ARDS trial, and is not cited in the
trial's protocol [21], it revealed a division of opinion in
the expert clinical community concerning the choice of
tidal volumes: 45% and 48% of respondents thought tidal
volumes of 5–9 ml/kg and 10–13 ml/kg, respectively,
most appropriate in patients with ARDS.
A survey conducted expressly to evaluate practitioners'
beliefs concerning a set of clinical questions may support
a claim of clinical equipoise for a particular trial. For
example, a survey was conducted, and reported [22], in
support of a proposed trial comparing early and delayed
delivery of preterm fetuses. The results revealed that the
respondents did not agree about the benefit of delivery for
preterm infants that were failing to thrive. The formal
measurement of clinical belief revealed collective uncer-
tainty, providing impetus and justification for a related
RCT. Responses by practitioners to survey questions may
also represent statements of prior beliefs concerning treat-
ment effects, used expressly when Bayesian methods are
used for interim results monitoring and final analysis of
outcome measures.[23] Parmar and colleagues reported
the monitoring of two RCTs (lung, and head and neck
cancer) by Bayesian methods after establishing "sceptical"
and "enthusiastic" prior distributions through a survey of
participating physicians.[24]
A formal survey of relevant experts is also consistent with
the views of potential trial participants on the implication
of expert opinion on their decisions to enroll in a trial. A
study conducted by Johnson et al. [25] showed that half
the respondents perceived a trial as unethical when clini-
cian equipoise was disturbed beyond 70:30, and less than
3 percent would consider trials morally justifiable when
clinician equipoise is disturbed beyond 80:20.
We propose that, in the appropriate clinical circum-
stances, trialists should adopt a low threshold for con-
ducting a formal survey in support of a RCT, and present
the results to research ethics committees and prospective
participants. The survey should be conducted as close to
the anticipated start of the trial as feasible to ensure that
the assessment of clinical equipoise is informed by the
current practice of relevant practitioners.
Publication of the proposed trial's protocol
Trialists should strongly consider soliciting critical
appraisal of a proposed RCT by publishing the trial proto-
col before it is finalized, and prior to its submission to
research ethics committees for review. Godlee [26] has
summarized reasons to publish protocols : readers may
submit critical comments leading to improvements in
trial design; publication should be coupled with trial reg-
istration; readers may compare what was declared in the
protocol with what was subsequently done; and investiga-
tors will more easily appreciate what research is being
conducted in their areas of interest. The first of these is
particularly relevant to this discussion – trialists should
devote a section of the protocol to the rationale for the
choice of experimental and control interventions.
An argument will be made that trialists or sponsors will
generally be unwilling to publish their protocols because
of perceived adverse academic, proprietary or commercial
implications. But this argument places the interests of tri-
alists and sponsors ahead of those of potential partici-
pants and the public's health, without justification. As one
of us (HM) has proposed [27], research ethics committees
should make research approval contingent on trial regis-
tration, and the latter should provide summary details of
the trial's objectives, comparator interventions and
design, sufficient to permit a preliminary judgment con-
cerning clinical equipoise.
Concluding comments
RCTs should produce results that resolve or diminish
uncertainty concerning the relative merits of comparator
interventions. Randomization of patients among compa-
rator interventions should promote patient-participants'
interests in securing the best treatment under conditions
of epistemic uncertainty. Assurance of clinical equipoise
and the proper choice of a control intervention is critical
to these ends. If evidence were to emerge that results of
RCTs consistently and significantly favor experimental
over control interventions, in aggregate, this form of bio-
medical research would be jeopardized. At present, there
is evidence, albeit limited, that this is not the case, [28–
31] although concern has been expressed about preserva-
tion of the uncertainty principle in an analysis of RCTs in
multiple myeloma sponsored by industry.[31] More
research of this type is needed.
Trialists and research ethics committees should verify a
state of reasoned uncertainty in relation to an up-to-date
synthesis and appraisal of existent knowledge and the
informed beliefs of colleagues. Physicians may then con-
fidently propose trial enrollment to their eligible patients
as an act of therapeutic beneficence.
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